These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37342459)

  • 1. Role of silymarin in the management of deranged liver function in non-alcoholic steatohepatitis: a case report.
    Lee YY; Tee V
    Drugs Context; 2023; 12():. PubMed ID: 37342459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silymarin and management of liver function in non-alcoholic steatohepatitis: a case report.
    Hashem A
    Drugs Context; 2023; 12():. PubMed ID: 37313039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silymarin treatment and reduction of liver enzyme levels in non-alcoholic fatty liver disease: a case report.
    Chantarojanasiri T
    Drugs Context; 2023; 12():. PubMed ID: 37077770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silymarin in the management of liver enzyme activity in steatohepatitis: a case report.
    Torre A
    Drugs Context; 2023; 12():. PubMed ID: 37077767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of non-alcoholic fatty liver disease incidentally detected during other medical assessments.
    Lee YY; Tee V
    Drugs Context; 2023; 12():. PubMed ID: 37205125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatoprotective effects of silymarin in management of liver injury caused by tuberculosis treatment.
    Lee YY; Tee V
    Drugs Context; 2023; 12():. PubMed ID: 37313040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic liver disease and management with silymarin: an introductory review of a clinical case collection.
    Angelico F
    Drugs Context; 2024; 13():. PubMed ID: 38332944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of silymarin as antioxidant in clinical management of chronic liver diseases: a narrative review.
    Aghemo A; Alekseeva OP; Angelico F; Bakulin IG; Bakulina NV; Bordin D; Bueverov AO; Drapkina OM; Gillessen A; Kagarmanova EM; Korochanskaya NV; Kucheryavii UA; Lazebnik LB; Livzan MA; Maev IV; Martynov AI; Osipenko MF; Sas EI; Starodubova A; Uspensky YP; Vinnitskaya EV; Yakovenko EP; Yakovlev AA
    Ann Med; 2022 Dec; 54(1):1548-1560. PubMed ID: 35635048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Silymarin in the treatment of chronic liver diseases: past and future].
    Fehér J; Lengyel G
    Orv Hetil; 2008 Dec; 149(51):2413-8. PubMed ID: 19073452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review and expert opinion on MAFLD, oxidative stress and multifunctional management.
    Angelico F; Alcantara-Payawal D; Rani RA; Mustafa N; Thongtang N; Chaiteerakij R; Bunchorntavakul C; Sukonthasarn A
    Drugs Context; 2024; 13():. PubMed ID: 38264403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silymarin for Treating Toxic Liver Disease: International Consensus Recommendations.
    Gillessen A; Angelico F; Chen J; Lu L; Lucena MI; Fu Q; Xie Q; Andrade RJ; Xie W; Xu X; Yu Y; Mao YM; Nan Y
    Gastro Hep Adv; 2022; 1(5):882-893. PubMed ID: 39131840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of silymarin in patients with non-alcoholic fatty liver disease - the Siliver trial: a study protocol for a randomized controlled clinical trial.
    de Avelar CR; Nunes BVC; da Silva Sassaki B; Dos Santos Vasconcelos M; de Oliveira LPM; Lyra AC; Bueno AA; de Jesus RP
    Trials; 2023 Mar; 24(1):177. PubMed ID: 36899430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Oral Administration of Silymarin in a Juvenile Murine Model of Non-alcoholic Steatohepatitis.
    Marin V; Gazzin S; Gambaro SE; Dal Ben M; Calligaris S; Anese M; Raseni A; Avellini C; Giraudi PJ; Tiribelli C; Rosso N
    Nutrients; 2017 Sep; 9(9):. PubMed ID: 28895929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silymarin suppresses hepatic stellate cell activation in a dietary rat model of non-alcoholic steatohepatitis: analysis of isolated hepatic stellate cells.
    Kim M; Yang SG; Kim JM; Lee JW; Kim YS; Lee JI
    Int J Mol Med; 2012 Sep; 30(3):473-9. PubMed ID: 22710359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of silymarin in the treatment of liver diseases.
    Saller R; Meier R; Brignoli R
    Drugs; 2001; 61(14):2035-63. PubMed ID: 11735632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study of clinical efficiency of essential phospholipids and silymarin combination in nonalcoholic and alcoholic steatohepatitis].
    Iakimchuk GN; Gendrikson LN
    Eksp Klin Gastroenterol; 2011; (7):64-9. PubMed ID: 22364002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chitosan-functionalized lipid-polymer hybrid nanoparticles for oral delivery of silymarin and enhanced lipid-lowering effect in NAFLD.
    Liang J; Liu Y; Liu J; Li Z; Fan Q; Jiang Z; Yan F; Wang Z; Huang P; Feng N
    J Nanobiotechnology; 2018 Sep; 16(1):64. PubMed ID: 30176941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic Fatty liver disease: a randomized controlled pilot study.
    Hajiaghamohammadi AA; Ziaee A; Oveisi S; Masroor H
    Hepat Mon; 2012 Aug; 12(8):e6099. PubMed ID: 23087748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis.
    Lombardi R; Onali S; Thorburn D; Davidson BR; Gurusamy KS; Tsochatzis E
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011640. PubMed ID: 28358980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Herbal Medicine in the Treatment of Non-Alcoholic Fatty Liver Diseases-Efficacy, Action Mechanism, and Clinical Application.
    Xu Y; Guo W; Zhang C; Chen F; Tan HY; Li S; Wang N; Feng Y
    Front Pharmacol; 2020; 11():601. PubMed ID: 32477116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.